These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

457 related items for PubMed ID: 31390268

  • 1. Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy.
    Lee YH, Kim SH, Kang JM, Heo JH, Kim DJ, Park SH, Sung M, Kim J, Oh J, Yang DH, Lee SH, Lee SY.
    Am J Physiol Renal Physiol; 2019 Oct 01; 317(4):F767-F780. PubMed ID: 31390268
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice.
    Gangadharan Komala M, Gross S, Mudaliar H, Huang C, Pegg K, Mather A, Shen S, Pollock CA, Panchapakesan U.
    PLoS One; 2014 Oct 01; 9(11):e108994. PubMed ID: 25369239
    [Abstract] [Full Text] [Related]

  • 3. Chloroquine and amodiaquine enhance AMPK phosphorylation and improve mitochondrial fragmentation in diabetic tubulopathy.
    Jeong HY, Kang JM, Jun HH, Kim DJ, Park SH, Sung MJ, Heo JH, Yang DH, Lee SH, Lee SY.
    Sci Rep; 2018 Jun 08; 8(1):8774. PubMed ID: 29884802
    [Abstract] [Full Text] [Related]

  • 4. ESRRA modulation by empagliflozin mitigates diabetic tubular injury via mitochondrial restoration.
    Yang K, Liang W, Hu H, Zhang Z, Hao Y, Song Z, Yang L, Hu J, Chen Z, Ding G.
    Cell Signal; 2024 Oct 08; 122():111308. PubMed ID: 39059756
    [Abstract] [Full Text] [Related]

  • 5. Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy?
    Panchapakesan U, Pegg K, Gross S, Komala MG, Mudaliar H, Forbes J, Pollock C, Mather A.
    PLoS One; 2013 Oct 08; 8(2):e54442. PubMed ID: 23390498
    [Abstract] [Full Text] [Related]

  • 6. Empagliflozin improves diabetic renal tubular injury by alleviating mitochondrial fission via AMPK/SP1/PGAM5 pathway.
    Liu X, Xu C, Xu L, Li X, Sun H, Xue M, Li T, Yu X, Sun B, Chen L.
    Metabolism; 2020 Oct 08; 111():154334. PubMed ID: 32777444
    [Abstract] [Full Text] [Related]

  • 7. The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway.
    Meng Z, Liu X, Li T, Fang T, Cheng Y, Han L, Sun B, Chen L.
    Int Immunopharmacol; 2021 May 08; 94():107492. PubMed ID: 33647823
    [Abstract] [Full Text] [Related]

  • 8. Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis.
    Ojima A, Matsui T, Nishino Y, Nakamura N, Yamagishi S.
    Horm Metab Res; 2015 Aug 08; 47(9):686-92. PubMed ID: 25611208
    [Abstract] [Full Text] [Related]

  • 9. No Cytotoxic and Inflammatory Effects of Empagliflozin and Dapagliflozin on Primary Renal Proximal Tubular Epithelial Cells under Diabetic Conditions In Vitro.
    Baer PC, Koch B, Freitag J, Schubert R, Geiger H.
    Int J Mol Sci; 2020 Jan 08; 21(2):. PubMed ID: 31936266
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging.
    Kidokoro K, Cherney DZI, Bozovic A, Nagasu H, Satoh M, Kanda E, Sasaki T, Kashihara N.
    Circulation; 2019 Jul 23; 140(4):303-315. PubMed ID: 30773020
    [Abstract] [Full Text] [Related]

  • 11. PGC1α Activators Mitigate Diabetic Tubulopathy by Improving Mitochondrial Dynamics and Quality Control.
    Lee SY, Kang JM, Kim DJ, Park SH, Jeong HY, Lee YH, Kim YG, Yang DH, Lee SH.
    J Diabetes Res; 2017 Jul 23; 2017():6483572. PubMed ID: 28409163
    [Abstract] [Full Text] [Related]

  • 12. A role for tubular Na+/H+ exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin.
    Onishi A, Fu Y, Patel R, Darshi M, Crespo-Masip M, Huang W, Song P, Freeman B, Kim YC, Soleimani M, Sharma K, Thomson SC, Vallon V.
    Am J Physiol Renal Physiol; 2020 Oct 01; 319(4):F712-F728. PubMed ID: 32893663
    [Abstract] [Full Text] [Related]

  • 13. SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in db/db Mice, a Model of Type 2 Diabetes.
    Korbut AI, Taskaeva IS, Bgatova NP, Muraleva NA, Orlov NB, Dashkin MV, Khotskina AS, Zavyalov EL, Konenkov VI, Klein T, Klimontov VV.
    Int J Mol Sci; 2020 Apr 23; 21(8):. PubMed ID: 32340263
    [Abstract] [Full Text] [Related]

  • 14. Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts.
    Mizuno M, Kuno A, Yano T, Miki T, Oshima H, Sato T, Nakata K, Kimura Y, Tanno M, Miura T.
    Physiol Rep; 2018 Jun 23; 6(12):e13741. PubMed ID: 29932506
    [Abstract] [Full Text] [Related]

  • 15. Renal protective effects of empagliflozin via inhibition of EMT and aberrant glycolysis in proximal tubules.
    Li J, Liu H, Takagi S, Nitta K, Kitada M, Srivastava SP, Takagaki Y, Kanasaki K, Koya D.
    JCI Insight; 2020 Mar 26; 5(6):. PubMed ID: 32134397
    [Abstract] [Full Text] [Related]

  • 16. Organic anion transporter OAT3 enhances the glucosuric effect of the SGLT2 inhibitor empagliflozin.
    Fu Y, Breljak D, Onishi A, Batz F, Patel R, Huang W, Song P, Freeman B, Mayoux E, Koepsell H, Anzai N, Nigam SK, Sabolic I, Vallon V.
    Am J Physiol Renal Physiol; 2018 Aug 01; 315(2):F386-F394. PubMed ID: 29412698
    [Abstract] [Full Text] [Related]

  • 17. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
    Aroor AR, Das NA, Carpenter AJ, Habibi J, Jia G, Ramirez-Perez FI, Martinez-Lemus L, Manrique-Acevedo CM, Hayden MR, Duta C, Nistala R, Mayoux E, Padilla J, Chandrasekar B, DeMarco VG.
    Cardiovasc Diabetol; 2018 Jul 30; 17(1):108. PubMed ID: 30060748
    [Abstract] [Full Text] [Related]

  • 18. Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice.
    Pennig J, Scherrer P, Gissler MC, Anto-Michel N, Hoppe N, Füner L, Härdtner C, Stachon P, Wolf D, Hilgendorf I, Mullick A, Bode C, Zirlik A, Goldberg IJ, Willecke F.
    Sci Rep; 2019 Nov 29; 9(1):17937. PubMed ID: 31784656
    [Abstract] [Full Text] [Related]

  • 19. Beneficial Effect of Chloroquine and Amodiaquine on Type 1 Diabetic Tubulopathy by Attenuating Mitochondrial Nox4 and Endoplasmic Reticulum Stress.
    Kang JM, Lee HS, Kim J, Yang DH, Jeong HY, Lee YH, Kim DJ, Park SH, Sung M, Kim J, An HJ, Lee SH, Lee SY.
    J Korean Med Sci; 2020 Sep 14; 35(36):e305. PubMed ID: 32924342
    [Abstract] [Full Text] [Related]

  • 20. Disruption of renal tubular mitochondrial quality control by Myo-inositol oxygenase in diabetic kidney disease.
    Zhan M, Usman IM, Sun L, Kanwar YS.
    J Am Soc Nephrol; 2015 Jun 14; 26(6):1304-21. PubMed ID: 25270067
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.